Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 5/20 | 0.43 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.42 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710125 | 0.95 | SERPINE1 (0.48) | SERPINE1NHERF1STK33PLCG2KDM4E | |
| SCHEMBL6713933 | 0.93 | RXFP1 (0.41) | KCNMA1STK33AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL6708019 | 0.93 | GPR35 (0.44) | NHERF1STK33PLCG2GAAKDR | |
| SCHEMBL6711906 | 0.92 | NHERF1 (0.46) | NHERF1STK33PLCG2GAA | |
| SCHEMBL6710112 | 0.91 | MAP3K5 (0.45) | NHERF1STK33PLCG2KDM4ERXFP1 | |
| SCHEMBL6708855 | 0.90 | KDR (0.45) | NHERF1STK33PLCG2KDM4ENPSR1 | |
| SCHEMBL6708007 | 0.90 | MEN1 (0.41) | STK33AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6710319 | 0.90 | CHRNB2 (0.43) | SERPINE1NHERF1PLCG2 | |
| SCHEMBL6708820 | 0.90 | PARP14 (0.41) | NHERF1PLCG2KDM4EL3MBTL1 | |
| SCHEMBL6710216 | 0.89 | KCNMA1 (0.46) | NHERF1KCNMA1PLCG2GAAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | SERPINE1 2108/4885NHERF1 1641/4885KCNMA1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.